Compare · IBO vs NVO
IBO vs NVO
Side-by-side comparison of Impact BioMedical Inc. (IBO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IBO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 3115.7x IBO ($61.4M).
- Over the past year, IBO is up 22.5% and NVO is down 44.9% - IBO leads by 67.4 points.
- NVO has hit the wire 8 times in the past 4 weeks while IBO has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for IBO).
- Company
- Impact BioMedical Inc.
- Novo Nordisk A/S
- Price
- $0.58-3.82%
- $43.40+1.43%
- Market cap
- $61.4M
- $191.15B
- 1M return
- -4.75%
- -7.70%
- 1Y return
- +22.51%
- -44.91%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2024
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IBO
- SEC Form 10-Q filed by Impact BioMedical Inc.
- SEC Form 144 filed by Impact BioMedical Inc.
- SEC Form S-8 POS filed by Impact BioMedical Inc.
- SEC Form S-8 POS filed by Impact BioMedical Inc.
- Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans
- SEC Form 4 filed by Macko Todd D
- SEC Form 4 filed by Grady Jason
- SEC Form 10-K filed by Impact BioMedical Inc.
- Impact BioMedical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Large owner Dss, Inc. sold $88,006 worth of shares (161,000 units at $0.55), decreasing direct ownership by 23% to 545,024 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care